Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Vassilis Georgoulias, MD
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
The combination of chemotherapy with radiotherapy remains the standard of therapy for patients with stage III NSCLC. A recent phase II study has presented encouraging data regarding the ad...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to establish the objective response rate (complete response + partial response) following treatment with VELCADE in combination with cisplatin plus g...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
Investigators propose to assess,the safety and tolerability profile (number of participants with adverse events)of bevacizumab (Avastin) when combined with standard chemotherapy as first l...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
This randomized phase II trial will compare the efficacy and toxicity of Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin in patients with pancreatic cancer.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Vassilis Georgoulias, MD
Update Il y a 4 ans
Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
To evaluate the efficacy and toxicity of erlotinib as first line treatment in patients with locally advanced/metastatic (stages IIIB/IV) NSCLC, with clinical predictors of response to tyro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2